WALTHAM, MA • 2020-01-14

BostonGene Announces Scientific Collaboration with the Vaccine and Immunotherapy Center at Massachusetts General Hospital

5 min to read

Sophisticated Data Analytics to Validate Tumor Molecular Profiles in Cancer Patients
Sophisticated Data Analytics to Validate Tumor Molecular Profiles in Cancer Patients

WALTHAM, MA – January 14, 2020 - BostonGene Corporation (BostonGene), a biomedical software company, today announced its collaboration with the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital.

BostonGene performs a computational analysis of a patient's genomics and transcriptomics data from solid tumors including Lung Cancer and Head and Neck Cancer. In parallel, MGH VIC team conducts mass cytometry analysis of tissue of same patients. A correlation analysis is then employed to demonstrate the power of the computational algorithms in the assessment of the intratumoral cellular composition including stromal and immune components. The results of this collaboration highlight the powerful advantage of NGS data analysis in comparison to conventional techniques to more fully characterize the tumor.

Using small amounts of tissue, BostonGene provides an accurate, patient tailored report for physicians. The report includes a visually-appealing and self-explanatory tumor schematics, called MF Portrait™, depicting tumor activity, tumor cellular composition, activity of immune-microenvironment and other tumor-associated processes.

“Our collaboration with BostonGene is aimed at understanding the pathogenesis of each person’s cancer and ultimately having a positive impact on patient care by enabling personalized cancer treatments,” said Mark Poznansky, MD, PhD, at Massachusetts General Hospital.

“BostonGene provides the solution necessary for oncologists to evaluate NGS data in combination with all relevant clinical knowledge to determine the best personalized care for the individual patient,” said Andrew Feinberg, President and CEO of BostonGene. “We are excited to collaborate with VIC at MGH to demonstrate how our unique solution for tailored treatment options improves outcomes for cancer patients.”

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin Keleher O'Reilly

Senior Director